Clinical Trials · NCT06719011
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 178
- Start date
- Dec 2024
- Locations
- 2 sites, United States
- Primary endpoint
- Part A: Number of treatment emergent adverse events (TEAE) reported by participants exposed to NNC0174 1213